|
Post by qwertqwert on Apr 14, 2021 20:24:28 GMT -5
Expected to file with fda for drug approval this month. Since UTHR paid 105 million to shorten the FDA review by 4 months, or $860,000 a day. If I am Martine knowing each day is worth $860,000 I am probably very focused on filing for approval ASAP. UTHR was waiting for approval on Tyvaso/ILD expanded label and they got that. Seems like someone knows something on the timing and was buying today! But who was buying? was it "anonymous"?
|
|
|
Post by factspls88 on Apr 15, 2021 14:51:20 GMT -5
Can't get no satisfaction - with this stock.
|
|
|
Post by peppy on Apr 15, 2021 15:04:25 GMT -5
MNKD Nasdaq real time volume, 2,672,161 shares. MNKD Nasdaq summary volume, 4,201,706 shares. Avg. Volume 6,222,555
$4.30. -0.26 (-5.70%) At close: 4:00PM EDT
|
|
|
Post by lazyb767 on Apr 15, 2021 15:06:03 GMT -5
Can't get no satisfaction - with this stock. Up, down, all around...
|
|
|
Post by mytakeonit on Apr 15, 2021 15:24:31 GMT -5
Not sure what you all are talking about ... I see that we are still up 6 cents going into script day. AND MORE SO, headed into double digit royalties.
But, that's mytakeonit
|
|
|
Post by peppy on Apr 15, 2021 16:23:44 GMT -5
MNKD Nasdaq real time volume, 2,672,161 shares. MNKD Nasdaq summary volume, 4,201,706 shares. Avg. Volume 6,222,555 $4.30. -0.26 (-5.70%) At close: 4:00PM EDT After-Hours Volume 1,009,262 16:13:25 $4.40 518,500 16:10:10 $4.40 134,300 and more. www.nasdaq.com/market-activity/stocks/mnkd/after-hours-trades
|
|
|
Post by mymann on Apr 15, 2021 17:24:19 GMT -5
So what does that mean? After hour shenanigans.
|
|
|
Post by porkini on Apr 15, 2021 17:26:53 GMT -5
So what does that mean? After hour shenanigans. Maybe, but >1M shares worth?
|
|
|
Post by longliner on Apr 15, 2021 17:28:55 GMT -5
So what does that mean? After hour shenanigans. It means 652,800 shares of MNKD were purchased after hours at $4.40 per share.
|
|
|
Post by peppy on Apr 16, 2021 15:54:35 GMT -5
MNKD Nasdaq real time volume, 1,929,400 shares. MNKD Nasdaq summary volume, 2,650,182 shares. Avg. Volume 6,242,555 $4.18. -0.12 (-2.79%) At close: 4:00PM EDT Weekly Chart.
|
|
|
Post by falconquest on Apr 16, 2021 18:51:37 GMT -5
Can't get no satisfaction - with this stock. Up, down, all around... Might as well just be Howlin' Around your Happy Home.....
|
|
|
Post by bones1026 on Apr 16, 2021 22:23:14 GMT -5
Might as well just be Howlin' Around your Happy Home.....
Tik Tok..🤫
|
|
|
Post by prcgorman2 on Apr 17, 2021 11:25:54 GMT -5
What is the material difference between MNKD a year ago and MNKD today? About a 4x increase in share price with an apparent floor above $3. Based on what?
Sales have been stagnant thanks to COVID-19. The fact that they haven’t dropped dramatically is a testament to customer satisfaction. And, they seem to be trickling up again which frankly kind of amazes me. We’ll be forever at getting rich off Afrezza at this rate, but I’m pretty confident the folks who’ve said trials and PBM discounts are the path to material sales competitive with other prandial insulins are correct. It definitely isn’t Direct To Customer (DTC) advertising. (I have my doubts about VDEX being the difference, but I do appreciate their investment and hope they enjoy spectaclar success and prove me wildly wrong.)
We could hope the Reddit kiddiess got into the act and made the difference since last year but that’s doubtful.
So what has driven the volume into the 3M to 6M shares per day range? Refinance and proximity to UTHR announcements, and whatever visibility that gives to investors.
Buyers have led sellers overall even with a substantial increase in share borrowing. I don’t expect a squeeze from the increased Short Interest Rate (SIR), but I’ll laugh my tail off if one materializes. Mannkind management are not idle. Good grief, how many CEOs annex a PhD while taking over a struggling small company? It’s not super-human but it sure as heck is evidence of smarts, drive, and effort. The buzy boys and girls at Mannkind are capable of a surprise, and they’ve got irons in the fire, so maybe shorts will get burned. :-)
|
|
|
Post by mymann on Apr 17, 2021 12:14:33 GMT -5
Just one more deal with another drug maker using technophere would set us on the path for "embarrassment of riches ". Hoping it's a vaccine maker and Bill Gates.
|
|
|
Post by Chris-C on Apr 17, 2021 13:29:58 GMT -5
What is the material difference between MNKD a year ago and MNKD today? About a 4x increase in share price with an apparent floor above $3. Based on what? Sales have been stagnant thanks to COVID-19. The fact that they haven’t dropped dramatically is a testament to customer satisfaction. And, they seem to be trickling up again which frankly kind of amazes me. We’ll be forever at getting rich off Afrezza at this rate, but I’m pretty confident the folks who’ve said trials and PBM discounts are the path to material sales competitive with other prandial insulins are correct. It definitely isn’t Direct To Customer (DTC) advertising. (I have my doubts about VDEX being the difference, but I do appreciate their investment and hope they enjoy spectaclar success and prove me wildly wrong.) We could hope the Reddit kiddiess got into the act and made the difference since last year but that’s doubtful. So what has driven the volume into the 3M to 6M shares per day range? Refinance and proximity to UTHR announcements, and whatever visibility that gives to investors. Buyers have led sellers overall even with a substantial increase in share borrowing. I don’t expect a squeeze from the increased Short Interest Rate (SIR), but I’ll laugh my tail off if one materializes. Mannkind management are not idle. Good grief, how many CEOs annex a PhD while taking over a struggling small company? It’s not super-human but it sure as heck is evidence of smarts, drive, and effort. The buzy boys and girls at Mannkind are capable of a surprise, and they’ve got irons in the fire, so maybe shorts will get burned. :-) prcgorman2 Well said, Sir. Having been an investor for a over a decade, I counsel myself regularly to keep my expectations realistic and my patience in "eco mode". The unexpected rise over the past year has been great, but it's been accompanied by some of the same monkey business we've seen in the past. It's really hard to tell if the move to the present level represents a gradual awakening by smart investors or the increased number of investors and traders with time, spare cash, and few alternatives to get a decent return on capital? We know for sure it is not Afrezza sales, although the numbers posted on this board are at best a barometer of the actual number of scripts being written. I, personally, don't think that completion of peds trials and approval wlll lead to a dramatic uptick in Afrezza sales either. I'd love to be proven wrong. Expansion in the UK, Europe and Asia would definitely help too. But the real value, as many here agree, is in the technosphere partnerships. There will be significant UTHR royalties, and sooner or later the RLS franchise may start bearing fruit But what we really need to kick start street recognition toward reasonable share price levels is a surprise announcement of another partnership beyond UTHR. Then suddenly, slow eyed investors will begin to see the possibilities beyond break even. Of the surprise announcements this company has made since I became an investor, it feels like the ratio of negative to positive types has been heavily weighted to the minus side. A surprise positive, share price moving, jaw opening wow factor announcement would be awesome. And I agree with you that the company is capable now of doing that. I've grown weary of short positions manufacturing their own paydays. I'm ready for payback and leveling the scoresheet or tipping it dramatically to the positive side for a change. GLTAL FTS
|
|